# CRBU — slm-full-cpu

## Metadata

ticker: CRBU
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: ee62bf827ddd13a4a2c20272343f929d2ade0962d247b1092832433180467394
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 576, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 181.951, "latency_s_total": 181.951, "parse_failure": 0, "prompt_tokens": 3132, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 551, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 174.423, "latency_s_total": 174.423, "parse_failure": 0, "prompt_tokens": 3121, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 147, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 80.649, "latency_s_total": 80.649, "parse_failure": 0, "prompt_tokens": 687, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 129, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 59.95, "latency_s_total": 59.95, "parse_failure": 0, "prompt_tokens": 681, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 212, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 91.116, "latency_s_total": 91.116, "parse_failure": 0, "prompt_tokens": 627, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 171, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 84.075, "latency_s_total": 84.075, "parse_failure": 0, "prompt_tokens": 660, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1009, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 117.578, "latency_s_total": 117.578, "parse_failure": 0, "prompt_tokens": 1704, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "CRBU",
  "company_name": "Caribou Biosciences, Inc.",
  "current_price": 1.135,
  "currency": "USD",
  "market_cap": 121680528.0,
  "forward_pe": -0.89841926,
  "week_52_high": 3.535,
  "week_52_low": 1.13,
  "financial_currency": "USD",
  "revenue": 10035000.0,
  "net_income": -103403000.0,
  "profit_margin_pct": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-05",
    "summary": "Item 1A. Risk Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes, before making an investment decision. These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect our company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future. Furthermore, the risks described below are not the only ones faci"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-13",
    "summary": "Item 1A. Risk Factors. There have been no material changes to the Risk Factors previously disclosed in Item 1A. to Part I of our Form 10-K. The risks described in our Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities. Unregistered Sales of Equity Securities during the Three Months Ended June 30, 2026 There were no unregistered sales of equity securities during the three months ended June 30, 2026. Item 5. Other Information. During the quarter ended June 30, 2026, none of our directo"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for ticker CRBU, here are the key takeaways regarding the company's financial position and risks:

**Financial Performance and Status**
*   **Significant Operating Losses:** The company has incurred significant operating losses every year since its inception. Net losses were $148.1 million for the year ended December 31, 2025, and $149.1 million for the year ended December 31, 2024.
*   **Accumulated Deficit:** As of December 31, 2025, the company had an accumulated deficit of $596.5 million.
*   **No Revenue:** The company has not commercialized any products and has never generated revenue from product sales. Almost all financial resources have been devoted to research and development, including preclinical and clinical activities.

**Capital Requirements and Liquidity**
*   **Need for Additional Financing:** The company requires substantial additional capital to conduct its planned pivotal clinical trial for vispa-cel and to implement operating plans for its product candidates, vispa-cel and CB-011.
*   **Current Cash Position:** As of December 31, 2025, the company held $142.8 million in cash, cash equivalents, and marketable securities. This is expected to fund current operations for at least the next 12 months, though this expectation relies on assumptions that may prove incorrect.
*   **Risk of Insufficient Funds:** The company currently does not have sufficient funds to conduct the planned pivotal clinical trial for vispa-cel. Failure to obtain additional financing would prevent the completion of development and commercialization for vispa-cel and/or CB-011.

**Future Expenses and Risks**
*   **Increasing Costs:** Expenses are expected to increase substantially as the company progresses clinical trials (particularly the pivotal trial for vispa-cel), hires employees, expands manufacturing capabilities, seeks regulatory approvals, and establishes commercialization infrastructure.
*   **Unpredictability:** The company cannot predict the extent of future losses or when it will become profitable, if at all. Even if profitable, it may not be able to sustain or increase profitability on a quarterly or annual basis.
*   **Additional Capital Needs:** Beyond current resources, the company will need additional capital for various factors, including clinical trial results, regulatory delays, workforce expansion, supply chain costs, patent maintenance, and potential litigation.
*   **Management Distraction:** Fundraising efforts may divert management from day-to-day activities, potentially adversely affecting the development and commercialization of product candidates. There is no certainty that additional funding will be available when needed or on acceptable terms.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $148.1 million in 2025 and $149.1 million in 2024, resulting in an accumulated deficit of $596.5 million as of December 31, 2025. The company has never generated revenue from product sales and anticipates continued operating losses for the foreseeable future.
*   **Inability to Achieve Profitability:** The company may not be able to achieve or sustain profitability, and even if it does, it may not be able to sustain or increase profitability on a quarterly or annual basis. The extent of future losses and the timeline for profitability are unpredictable.
*   **Need for Substantial Financing:** The company requires substantial additional financing to conduct its planned pivotal clinical trial for vispa-cel and to implement operating plans for its vispa-cel and CB-011 product candidates. As of December 31, 2025, the company had $142.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least 12 months, but this expectation is based on assumptions that may prove incorrect.
*   **Failure to Obtain Financing:** If the company fails to obtain additional financing, it will be unable to complete the development and commercialization of its vispa-cel and/or CB-011 product candidates. Specifically, without additional funds, the company cannot initiate the pivotal clinical trial for vispa-cel or develop CB-011 beyond dose expansion.
*   **High Costs of Development and Commercialization:** Costs increase substantially as product candidates advance through clinical phases with greater numbers of patients. The company expects significant expenses related to clinical trials, hiring, intellectual property, regulatory approvals, manufacturing, and establishing sales and marketing infrastructure.
*   **Operational and Regulatory Risks:** Risks include delays or failures in clinical trials, safety issues, regulatory challenges, difficulties in receiving regulatory clearances, and the need to establish manufacturing capabilities and supply chains.
*   **Litigation and Public Company Costs:** The company faces risks associated with operating as a public company, including defending against securities class action litigation and other legal costs.
*   **Management Distraction:** Additional fundraising efforts may divert management’s attention from day-to-day activities, adversely affecting the ability to develop and commercialize product candidates.
*   **Uncertainty of Funding Availability:** There is no certainty that additional funding will be available when needed, on acceptable terms, or at all.

## Pre-written sections (judge input)

### Financial Health

Caribou Biosciences, Inc. (CRBU) currently trades at $1.135 with a market capitalization of approximately $121.7 million. The company reported revenue of $10.04 million but incurred a net loss of $103.4 million, resulting in a negative profit margin and a forward P/E ratio of -0.90. This significant net loss highlights the firm's ongoing reliance on capital raises to fund its pre-revenue or early-stage biotechnology operations. Investors should note that the stock is trading near its 52-week low of $1.13, reflecting the high-risk profile associated with its current financial losses.

### Recent Developments

Caribou Biosciences continues to face significant financial headwinds, evidenced by a net loss of approximately $103.4 million and a market capitalization hovering near $121.7 million. The company’s stock is trading at the lower end of its 52-week range, reflecting ongoing investor caution regarding its path to profitability. Recent SEC filings indicate no material changes to risk factors or unregistered equity sales, suggesting a period of operational stability despite the lack of positive catalysts. Investors should remain vigilant as the company navigates high burn rates and competitive pressures in the biotechnology sector.

### SEC Filing Highlights
Caribou Biosciences reported a net loss of $148.1 million for the year ended December 31, 2025, maintaining its status as a pre-revenue company with an accumulated deficit of $596.5 million. The firm holds $142.8 million in cash and equivalents, which management estimates will fund operations for at least the next 12 months. However, the company explicitly states it lacks sufficient capital to complete the pivotal clinical trial for vispa-cel without securing additional financing. Consequently, CRBU faces significant liquidity risks, as future expenses will rise substantially during clinical development and regulatory approval processes. Failure to obtain necessary funds could prevent the completion and commercialization of its key product candidates, vispa-cel and CB-011.

### Risk Factors

*   **Substantial Financial Losses and Capital Requirements:** The company has incurred significant operating losses (accumulated deficit of $596.5 million as of Dec 31, 2025) and has never generated revenue from product sales. It requires substantial additional financing to fund pivotal clinical trials for vispa-cel and development of CB-011, with current cash reserves expected to last only at least 12 months based on uncertain assumptions.
*   **Uncertainty of Future Financing:** There is no guarantee that additional funding will be available when needed, on acceptable terms, or at all. Failure to secure necessary capital would prevent the company from completing clinical trials or advancing its product candidates, potentially forcing it to cease operations.
*   **Inability to Achieve Profitability:** The company may never achieve or sustain profitability due to the high costs of clinical development, regulatory approvals, manufacturing, and commercialization. The extent of future losses and the timeline for any potential profitability remain highly unpredictable.

## Audited (Exec Summary + Outlook)

### Executive Summary
Caribou Biosciences is a pre-revenue biotechnology firm specializing in CRISPR-based therapies, currently trading near its 52-week low with a market capitalization of approximately $121.7 million amidst significant operating losses. The stock is notable for its precarious liquidity position, as the company holds $142.8 million in cash that is explicitly insufficient to complete the pivotal clinical trial for its lead candidate, vispa-cel, without securing additional financing. The single most important near-term variable shaping the outcome is the company’s ability to successfully raise capital to bridge the funding gap required for clinical development.

### Outlook
The directional outlook for Caribou Biosciences is cautiously cautious, characterized by high binary risk tied directly to capital markets rather than operational execution. The primary headwind is the imminent liquidity constraint, where the existing cash reserve is explicitly insufficient to fund the pivotal trial for vispa-cel, creating a near-term existential threat if external financing is not secured. Key variables to monitor include the company’s ability to negotiate favorable terms for equity or debt financing and any updates regarding the clinical progress of vispa-cel and CB-011 that might de-risk the investment thesis for potential partners or investors. The view would strengthen only if the company successfully closes a financing round that extends its runway well beyond the current 12-month estimate, while it would weaken significantly if dilutive financing terms are unfavorable or if clinical milestones are delayed, further eroding investor confidence in the path to commercialization.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

## EXECUTIVE SUMMARY

---

CLAIM: "currently trading near its 52-week low"
LABEL: SUPPORTED
REASON: The source data shows current price = $1.135 and 52-week low = $1.13; the stock is $0.005 above its 52-week low, confirming it is trading near that low.

---

CLAIM: "market capitalization of approximately $121.7 million"
LABEL: SUPPORTED
REASON: Source data lists market_cap = $121,680,528, which rounds to approximately $121.7 million.

---

CLAIM: "the company holds $142.8 million in cash"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "As of December 31, 2025, the company held $142.8 million in cash, cash equivalents, and marketable securities."

---

CLAIM: "[cash] explicitly insufficient to complete the pivotal clinical trial for its lead candidate, vispa-cel, without securing additional financing"
LABEL: SUPPORTED
REASON: The SEC Filing Highlights pre-written section states: "the company explicitly states it lacks sufficient capital to complete the pivotal clinical trial for vispa-cel without securing additional financing," consistent with the RAG source data.

---

CLAIM: "vispa-cel" (named as lead candidate)
LABEL: SUPPORTED
REASON: vispa-cel is explicitly named as the lead candidate requiring a pivotal clinical trial in both the RAG SEC Highlights and the SEC Filing Highlights pre-written section.

---

## OUTLOOK

---

CLAIM: "existing cash reserve is explicitly insufficient to fund the pivotal trial for vispa-cel"
LABEL: SUPPORTED
REASON: RAG Risk Factors explicitly states: "without additional funds, the company cannot initiate the pivotal clinical trial for vispa-cel," consistent with the SEC filing summary provided.

---

CLAIM: "current 12-month estimate" (referring to the runway of at least 12 months)
LABEL: SUPPORTED
REASON: The RAG SEC Highlights states the $142.8 million "is expected to fund current operations for at least the next 12 months," and the pre-written SEC Filing Highlights section repeats this figure; the Outlook's reference to "the current 12-month estimate" accurately reflects this disclosed runway.

---

CLAIM: "clinical milestones … vispa-cel and CB-011"
LABEL: SUPPORTED
REASON: Both vispa-cel and CB-011 are explicitly named as product candidates in the RAG SEC Highlights and Risk Factors sections.

---

*No additional quantitative figures, price targets, specific ratios, percentages, or other forward-looking numbers appear in the Executive Summary or Outlook sections beyond those evaluated above.*
